Member Info for Brondby

Second cizzle tweet in as many days. Unusual. Ramping up comms?

https://twitter.com/CizzlePlc/status/1745848408869331182

There are shenanigans happening for sure, whether that is MMs or traders who have sold trying to bring the price down again. Small uncrossing trades at the bottom of the spread, tiny sells after each buy.

It worked yesteray when 66 pence(!) of sells over two trades and bid was dripped from 2.3 to 2.2!!

12k at 2.40p

Stronger base has been building all the time with this consolidation. I could see 2.5p going this week. Next resistance is 3p.

Genuinely hope you make all that back, and more Widglide.🤞

In Charles Archers piece on ciz end September, he writes based on the annual report "You can assume there’s roughly £240,000 of cash left at hand today, leaving circa 3-4 months of runway"

So he reckoned they had cash to end Dec, before they even need to touch CDT.

Even at $4, that's 1.6 million dollars or 1.3m pounds.

Even at 100k per month expenditure (it was only 70k in annual report), that is a huge runway. CEO already stated funded to end of 2024 in a recent interview.

So unlikely a fundraise until after test IMO, at which point they will be raising a hell of a lot higher than agreed 2.1p loan facility.

True Techtonic

Perhaps we will see some delayed buys and sells later.

Is that an error?

Some very strange price action today on large numbers of shares changing hands. Do MMs know something we don't?

A lot of talk on here has focussed on the Lab Developed test, quite naturally I think as it is the short-term catalyst that proves the method and starts to deliver revenue. That in itself should transform the share price beyond its 10p IPO IMO.

But the real game changer, what moves us to £s must surely be the LFT style point of care test? I'm as much looking forward to an update on that as the LDT. Again, no timeframe given for this, but anyone on here with any experience of what is involved in achieving this next stage?

It did Greend100!

The interest in this area is also why I think successful trials on this Biotechne platform will make us an early takeover candidate. Gives companies a massive leap forward over their competition.

Techtonic,

Biotech takes ages. This fantastic innovation was in 2016. https://pubmed.ncbi.nlm.nih.gov/27867087/

Yes that's our very own ciz1b.

The Telegraph article is full of 'could one day', and specifically "... there are “several problems” that needed to be addressed before early detection tests could be used widely."

So doesn’t sound to me like its anywhere near market or scalable commercial stage.

I may have lost all chance to buy more sub 2p

Looks to me like 2.5 resistance will break today

A sure fire way to disappointment, frustration and eventually selling (usually at a loss) is to expect an RNS "any day now". Biotech and pharma take time. Unpredictable amounts of time.

Best to chill with no timetable (or a long timetable) - its much more relaxing and takes away all the stress!

30k of buys in the last 45 minutes.

At absolute bargain prices. Well played 👏

Indeed Greend100, that is the calculation we are making by holding tight (and in my case still buying more when price is low enough).

2.5 years ago, investors paid 10p for a potential test that was years away and had numerous obstacles to commercialisation still to be overcome. They would be hoping for multiples return on that investment, maybe x10, x20?

We get to pay 2.15p for the same prospects, with x4.65 better return, despite being just weeks/months from commercialisation with the risk greatly reduced after numerous hurdles overcome.

Not chucking that away for a trade on todays fastest mover!

My own view is we will have a commercial test before the end of April and the SP will be in the teens.

But I am not putting timescales on it. My cash is in here until a buyout or £s, however long that takes.

Now that is patience for you

I'm patiently waiting for PIs to lose patience, so I can buy more, at even cheaper prices Greend100. 👍

Ah, I thought it was just me and a sticky browser cache. Gone for everyone it seems.

VincentVega

The kind of thing ciz mention in the RNS from 10th August. Its by resolving these issues (and finding a suitable automated platform in Biotechne) that has allowed ciz to be confident to progress to clinical trials to establish the analytical performance required for an LDT.

"This follows significant progress in isolating additional new and specific monoclonal antibodies to the CIZ1B biomarker and incorporating these into a new high-throughput clinical diagnostic immunoassay platform. The recent developments meet key milestones to begin commercial clinical trials. The Company is now engaged in clinical trials design to support the validation and accreditation of the CIZ1B test prior to commercial launch."

"A key milestone for the Company was to take the proof of concept test for CIZ1B and develop an accredited and commercially viable assay that could be used in a laboratory to test for early stage lung cancer. A common first approach to achieve this, known as an enzyme-linked immunosorbent assay (ELISA), involves a multistep process of analysing multiple blood samples in either manual or robotic handling systems. A major breakthrough by the team at the University of York has significantly improved on this traditional approach using alternative high-throughput assay formats for CIZ1B, that will now be used as the basis for a commercial product.

The next steps are to finalise standard production and operating protocols and to commence clinical trials that should lead to an accredited Laboratory Developed (LDT) test for launch initially in the USA. "

Greend100

I'm fairly sure other labs would still need their own validation for an LDT, because of this part:

"This analytical validation is limited to the specific conditions, staff, equipment and patient population of the particular laboratory, so the findings of these laboratory-specific analytical validation are not meaningful outside of the laboratory that did the analysis"

But clearly with the experience of one lab under the belt, others should be easier and confidence of successful validation very high.

Main thing for me is that success at Corepath de-risks everything on commercialisation. We already know the test works from previous trials, but this is the first test on a platform designed for commercial scale.

This works, then we know revenue will follow, initially from wider rollout across the globe of similar lab acredited tests, or through the LFT style test - an RNS saying we have achieved that would have ciz multbag again on top of the first multibag! Assuming we aren't bought out before then of course.

Of course, all this starts with the test being validated analytically. But I'd be very surprised if they had moved to Corepath trials without high expectations around what those would likely achieve.

I should have said, ultimately ciz will want FDA approval, but this would be for a version of the test being used outside the lab (presumably the LFT style test that has been proposed)

But getting this LDT being used starts to bring in revenue, and also proves the performance characteristics of the test on the Biotechne platform.

I assume it also makes it easier for other labs to become certified to perform the test (though they presumably would have to go through the same validation process within their own lab).

Its also possible we get an RNS on progress of the LFT style test before the LDT clinical trials are complete. Or on plans in China (though I suspect that is waiting on Corepath trials to complete)